Active case finding among marginalised and vulnerable populations reduces catastrophic costs due to tuberculosis diagnosis

Hemant Deepak Shewade, Vivek Gupta, Srinath Satyanarayana, Atul Kharate, K.N. Sahai, Lakshmi Murali, Sanjeev Kamble, Madhav Deshpande, Naresh Kumar, Sunil Kumar, Prabhat Pandey, U.N. Bajpai, Jaya Prasad Tripathi, Soundappan Kathiveli, SriPriya Pandurangan, Subrat Mohanty, Vaibhav Haribhau Ghule, Karuna D. Sagili, Banuru Murulidhara Prasad, Sudhi Nath, Priyanka Singh, Kamlesh Singh, Ramesh Singh, Gurukartick Jayaraman, P. Rajeswaran, Binod Kumar Srivastava, Moumita Biswas, Gayadhar Mallick, Om Prakash Bera, A. James Jeyakumar Jaisinghi, Ali Jafar Naqvi, Prafulla Verma, Mohammed Salauddin Ansari, Prafulla C. Mishra, G. Sumesh, Sanjeeb Barik, Vijesh Mathew, Manas Ranjan Singh Lohar, Chandrashekhar S. Gaurkhide, Ganesh Parate, Sharifa Yasin Baie, Ishwar Kolli, Ashwin Kumar Bharadwaj, G. Venkatraman, K. Sathiyarayanarayanan, Jinesh Lal, Ashwini Kumar Sharma, Raghuram Rao, Ajay M.V. Kumar and Sarabjit Singh Chadha as members of the Askhya SAMVAD study group.

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

ABSTRACT

Background: There is limited evidence on whether active case finding (ACF) among marginalised and vulnerable populations mitigates the financial burden during tuberculosis (TB) diagnosis.

Objectives: To determine the effect of ACF among marginalised and vulnerable populations on prevalence and inequity of catastrophic costs due to TB diagnosis among TB-affected households when compared with passive case finding (PCF).

Methods: In 18 randomly sampled ACF districts in India, during March 2016 to February 2017, we enrolled all new sputum-smear-positive TB patients detected through ACF and an equal number of randomly selected patients detected through PCF. Direct (medical and non-medical) and indirect costs due to TB diagnosis were collected through patient interviews at their residence. We defined costs due to TB diagnosis as ‘catastrophic’ if the total costs (direct and indirect) due to TB diagnosis exceeded 20% of annual pre-TB household income. We used concentration curves and indices to assess the extent of inequity.

Results: When compared with patients detected through PCF (n = 231), ACF patients (n = 234) incurred lower median total costs (US$ 4.6 and 20.4, p < 0.001). The prevalence of catastrophic costs in ACF and PCF was 10.3 and 11.5% respectively. Adjusted analysis showed that patients detected through ACF had a 32% lower prevalence of catastrophic costs relative to PCF (adjusted prevalence rate (95% CI): 0.68 (0.69, 0.97)). The concentration indices (95% CI) for total costs in both ACF [-0.15 (-0.32, 0.11)] and PCF [-0.06 (-0.20, 0.08)] were not significantly different from the line of equality and each other. The concentration indices (95% CI) for catastrophic costs in both ACF [-0.60 (-0.81, -0.39)] and PCF [-0.58 (-0.78, -0.38)] were not significantly different from each other: however, both the curves had a significant distribution among the poorest quintiles.

Conclusion: ACF among marginalised and vulnerable populations reduced total costs and prevalence of catastrophic costs due to TB diagnosis, but could not address inequity.

CONTACT Hemant Deepak Shewade hemantjipmer@gmail.com International Union Against Tuberculosis and Lung Disease (The Union), South-East Asia Office, New Delhi, India

These authors contributed equally as senior authors.

Supplemental data for this article can be accessed here.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Tuberculosis (TB) is the leading cause of death among infectious diseases. In 2016, an estimated 10.4 million people developed TB, and 1.7 million died from it [1]. Despite TB diagnosis and treatment services being free under the national TB programmes, patients incur significant direct medical, direct non-medical and indirect costs due to TB care [2]. Measuring costs especially during diagnosis of TB is important because it is the most uncertain period during illness, and most of the social protection measures do not cover costs incurred during diagnosis [3–7]. A systematic review reported that the total cost due to TB care was equivalent to 39% (range: 4–148%) of the annual household income (AHI). Half of the total cost was incurred before TB treatment [8].

High costs due to TB diagnosis could be because of the way in which TB care services are organised. Patients have to visit health services on their own for diagnosis [passive case finding (PCF)], and only after TB diagnosis does the programme takes up active responsibility to care for them [9]. The process to reach the health facilities could be time-consuming, cumbersome and costly [10–12]. As TB services are integrated with the general health system, the geographical, financial and social access barriers to TB care are similar to the barriers of accessing the general health system [4,13]. Patients get trapped in a vicious circle of repeated visits to the same health care provider (HCP) or visits to multiple HCPs including private and traditional HCPs [8,10,11,14,15].

The World Health Organization’s End TB strategy envisages that by 2035, no TB-affected household should incur catastrophic costs due to TB care. One of its four principles is to ensure the protection and promotion of human rights, ethics and equity. Systematic screening of those at high risk for TB is a key component of the End TB strategy. Active case finding (ACF) can reduce the costs due to TB diagnosis through early case detection [3,9].

India accounted for 27% of the estimated global TB burden in 2016, which included 0.4 million TB deaths [1,16]. In line with the strategic vision of India’s revised national TB control programme (RNTCP) (2012–2017) [17], project Axshya (meaning ‘free of TB’) was implemented by the South-East Asia office of the International Union Against Tuberculosis and Lung Disease (The Union) [18–20]. Axshya SAMVAD (Sensitisation and Advocacy in Marginalised and Vulnerable Areas of the District) is the ACF strategy under the project. SAMVAD in Sanskrit language means ‘conversation’. It resulted in the detection of a large number of persons with presumptive pulmonary TB and sputum-smear-positive TB [21]. However, whether it mitigated the financial impact of the disease on the patient’s households is unknown [9,22].

Globally, there is only one study that assessed the effect of ACF (screening household and neighbourhood contacts) on catastrophic costs due to TB (Cambodia in 2012–2013); however, no adjusted analysis was performed. The effect of ACF on inequity in distribution of catastrophic costs was also not assessed [23]. Although there have been studies on patient costs due to TB care in India [24], studies on catastrophic costs are limited.

Hence, this study was conducted to determine the effect of ACF in marginalised and vulnerable populations on catastrophic costs (prevalence, intensity and inequity) due to TB diagnosis among TB-affected households when compared with PCF alone.

Methods

Study design

This was an observational analytic study involving primary as well as secondary data collection.

Study setting

India’s national TB programme

RNTCP infrastructure includes national-, state-, district- and sub-district-level administrative units. The district TB centres, sub-district level programme management units called as TB units (TUs – one for 250 000 to 500 000 population) and designated microscopy centres (DMCs – one for 50 000 to 100 000 population) for sputum microscopy work under the administrative control of the State TB officer. Patients with presumptive TB visit the DMCs for sputum examination and diagnosis. Laboratory registers maintained in each DMC contain details of each person who underwent sputum smear microscopy, and TB registers maintained at each TU indicate the number of TB patients treated under RNTCP [25]. TB diagnosis and treatment services under RNTCP are provided free of charge.

Axshya SAMVAD under project Axshya during 2016–2017

Funded by The Global Fund against AIDS, TB and Malaria, the goal of project Axshya was to enhance the reach and visibility of RNTCP services among marginalised and vulnerable population and mitigate the impact of TB [18–20]. In consultation with the State TB programme, Axshya districts (total of 285 districts in 18 states) and Axshya TUs were identified. Within an Axshya TU, activities (including Axshya SAMVAD) were preferentially targeted towards marginalised and vulnerable populations (see S1 Annex for the criteria used to define marginalised and
vulnerable populations). Each Axshya district had a district coordinator (DC) who was supervised by the assistant project manager, state technical consultant and project management unit at The Union South East Asia office in New Delhi, India.

Technical and operational guidelines for Axshya SAMVAD (2016–17) are provided in S1 Annex. Community volunteers, trained by DC, conducted house-to-house visits to create awareness about TB, identified presumptive TB patients (people with any one of: >2 weeks of cough, fever, loss of appetite, loss of weight) and referred to the nearest DMC for sputum examination. Sputum collection and transport were carried out after a documented ‘failed referral’ [18].

Study population and sampling

All sputum-smear-positive TB patients newly registered for treatment between March 2016 and February 2017 and belonging to marginalised and vulnerable population in Axshya districts constituted the study population. We randomly sampled (simple random sampling) 18 districts from the 285 Axshya districts of India considering the feasibility of data collection. The sampling frame for these districts excluded districts from north-eastern India (due to the difficulty in the logistics of collecting data in the hilly terrain). These 18 districts belonged to seven states (Figure 1).

At the beginning of every month (from April 2016 to March 2017) in every study district, the DC

Figure 1. Map of India depicting the randomly sampled Axshya districts ($n = 18$) under Axshya SAMVAD study, India (2016–17) [26]. *SAMVAD: Sensitisation and Advocacy in Marginalised and Vulnerable Areas of the District. Axshya SAMVAD: an active case finding strategy under project Axshya implemented by The Union, South East Asia office, New Delhi, India, across 285 districts of India. *Reprinted with permission of the International Union Against Tuberculosis and Lung Disease. © The Union [26].
prepared a line list of new sputum-smear-positive TB patients registered in the previous month. This was compiled at district level, and each patient was provided a unique identifier (state code–district code–TU code–year–registration number). The patients were classified into three groups and updated in the open-access tool-based model: exposed; unexposed and eligible; and unexposed but ineligible [26].

The operational definition for each group is summarised in Table 1. To summarise, the ‘exposed’ group included patients identified through ACF (Axshya SAMVAD), and the ‘unexposed’ group included patients that were identified by PCF (non-Axshya SAMVAD). ‘Unexposed and ineligible’ group contained patients with mixed or contaminated exposure: in other words, these patients were identified through PCF and Axshya SAMVAD activity was conducted in their village before the date of diagnosis [26].

All the ‘exposed’ patients were enrolled into the study. An equal number from the list ‘unexposed and eligible’ were randomly (simple random sampling) enrolled as ‘unexposed’ (1:1 ratio, exposed: unexposed), and all the ‘unexposed but ineligible’ were excluded from the study [26].

### Data collection

Data were collected between April 2016 and June 2017. Details of data-collection procedure, monitoring of data collection and quality control have been described elsewhere [26].

The questionnaire used for data collection was divided into two parts. Part I contained variables that were extracted by reviewing the TB treatment register, treatment card and project Axshya records (S2 Annex). Part II was an interviewer-administered, structured, closed-ended questionnaire administered during a subsequent residential visit (S3 Annex). The pre-TB AHI and number of family members were used to calculate the monthly income per capita (MIPC) at the time of data collection. Information on costs incurred were collected for every consultation between eligibility for sputum examination [fifteenth day of continuous cough or fever or the day of the first episode of haemoptysis (whichever was earlier)] and date of diagnosis. This included direct medical costs (consultation fee, investigations and medicines), direct non-medical costs (diagnosis-related transport) and indirect costs (patient’s income loss for the time spent on consultation).

We did not include information on costs after diagnosis (before treatment and during treatment) because all patients irrespective of whether they were detected through ACF or PCF received the same treatment under RNTCP.

### Analysis and statistics

#### Data management

Data collected were double entered, validated and analysed during July to December 2017 using EpiData software (version 3.1 for entry and version 2.2.2.183 for analysis; EpiData Association, Odense Denmark). An equity assessment and adjusted analysis were performed using STATA (version 12.1, copyright 1985–2011 StataCorp LP USA).

For classification for below the poverty line, we used the Indian MIPC cut-off of 972 INR (~US$ 15.3) and 1407 INR (~US$ 22.1) for rural and urban areas, respectively [27]. The results are presented in US$ using the average conversion rate of US$1 = 63.6 INR (January 2018).

We summarise below the details of data analysis. However, for further details on analysis, the readers may wish to refer to previous references [28–30].
Cost description, prevalence and intensity of catastrophic costs

Direct medical, direct non-medical, indirect and total costs (overall, public private) were described (in US$) using the median and interquartile range (IQR). Based on the MIPC, assuming 22 working days per month and eight working hours per day, we calculated the value in terms of money for each hour spent for consultation (indirect costs).

The total costs for TB diagnosis were calculated and defined as catastrophic if they exceeded 20% of pre-TB AHI [2]. Data on pre-TB AHI and number of family members were rarely recorded (in Part II of questionnaire). Hence, during the analysis, we used the average household size of 4.8 in the seven states (to which these 18 districts belonged) to derive the pre-TB AHI [31]. The intensity of catastrophic costs was measured as median-positive overshoot beyond the 20% threshold [30]. Positive overshoot was calculated among those with catastrophic costs by subtracting 20% from the total costs expressed as a proportion of annual pre-TB household income [30].

The operational definitions of various costs and indicators used are summarised in Box 1.

Effect of Axshya SAMVAD on catastrophic costs due to TB diagnosis

We did a confounder-adjusted analysis (causal modelling) for the association between Axshya SAMVAD (yes – exposure) and catastrophic costs due to TB diagnosis (yes – outcome) using log binomial regression after adjusting for clustering at district level. A complete case analysis was performed. Variables were considered as potential confounders if they were associated with exposure ($p < 0.05$ or programmatically or clinically significant difference) and outcome ($p < 0.20$) (for details, see Table S1). Age and gender were considered as potential confounders irrespective of the $p$ values. A potential confounder was retained in the model as a confounder if removing it resulted in a change in the beta coefficient for the exposure (Axshya SAMVAD) by more than 15% [32]. We did not adjust for the number of HCPs visited and the type of first HCP visited. We hypothesised that these were in the causal pathway between exposure and outcome and did not qualify as confounders. Association was summarised (inferred) using unadjusted and adjusted prevalence ratios (95% CI).

Assessment of equity

Income quintiles were generated by ranking the households based on MIPC. The distribution of total costs due to TB diagnosis were summarised across income quintiles as follows: (1) absolute total costs, (2) total costs as a proportion of pre-TB AHI and (3) proportion of households experiencing catastrophic costs.

Concentration curves and concentration indices (along with 95% CI) were used to assess the extent of inequity in the distribution of all the above three indicators (in y axis) against cumulatively ranked households (poorest to richest – x axis). The values of concentration indices range from +1 to –1; with positive values (concentration curve below the line of equality) suggesting disproportionate concentrations among the rich, and negative values (concentration curve above the line of equality) suggesting disproportionate concentrations among the poor [29,30]. For the indicator ‘total costs’, we assumed equity if the concentration curve and index revealed a significant distribution across the richest quintiles (positive concentration index, 95% CI not including zero). For the indicators, ‘total costs as a proportion of pre-TB AHI’ and ‘catastrophic costs’, we assumed equity if the concentration curve and index revealed an equal distribution across the quintiles (concentration curve not significantly different from the line of equality). A comparison of concentration curves across Axshya SAMVAD and non-Axshya SAMVAD groups was performed using dominance tests [30].

Results

Of 661 enrolled, 88 were excluded later, as it was found that they did not fit into the study participant definition. Of 573 eligible, patient interviews were not conducted for 108 due to patient non-availability during their visit to the residence. When compared with those interviewed ($n = 465$), those not interviewed ($n = 108$) were less likely to be patients registered through Axshya SAMVAD, from rural areas and with a sputum grading of 3+ at diagnosis (Table S2).

The 465 patients with completed interviews were included in the final analysis: 234 in the Axshya SAMVAD group and 231 in the non-Axshya SAMVAD group. The time taken between enrolment and interview is summarised in Table S3. Of 465, only one (<1%) was living with HIV, while the HIV status was unknown for 177 (38%) patients.

Baseline characteristics

The socio-demographic, clinical and health system level characteristics of the Axshya SAMVAD and non-Axshya SAMVAD groups are summarised in Table 2. Compared with the non-Axshya SAMVAD group, in the Axshya SAMVAD group the median MIPC was lower (US$ 15.7 versus 13.1, $p = 0.014$), and the proportion of households below the poverty line was higher (45.4% versus 51.9%, $p = 0.19$).
Table 2. Baseline characteristics of patients with new sputum-smear-positive TB enrolled in Axshya SAMVAD study across 18 randomly sampled districts in India, 2016–17 (n = 465).

| Variable                                                                 | Total [N = 465] | Axshya SAMVAD group [N = 234] | Non-Axshya SAMVAD group [N = 231] | p value* |
|--------------------------------------------------------------------------|----------------|-------------------------------|-----------------------------------|----------|
| **Socio-demographic characteristics**                                     |                |                               |                                   |          |
| Age (years)                                                              |                |                               |                                   |          |
| 15–44                                                                    | 251 (54)       | 111 (47)                      | 140 (61)                          | 0.009    |
| 45–64                                                                    | 163 (35)       | 91 (39)                       | 72 (31)                           |          |
| ≥65                                                                      | 50 (11)        | 32 (14)                       | 18 (8)                            |          |
| Missing                                                                  | 1 (<1)         | 0 (0)                         | 1 (<1)                            |          |
| Mean (SD)                                                                | 42 (17)        | 44 (17)                       | 40 (17)                           | 0.003    |
| **Gender**                                                               |                |                               |                                   |          |
| Male                                                                     | 307 (66)       | 153 (65)                      | 154 (67)                          |          |
| Female                                                                   | 157 (34)       | 81 (35)                       | 76 (33)                           |          |
| Missing                                                                  | 1 (<1)         | 0 (0)                         | 1 (<1)                            |          |
| **Residence**                                                            |                |                               |                                   |          |
| Urban                                                                    | 58 (12)        | 17 (7)                        | 41 (18)                           | <0.001   |
| Rural                                                                    | 402 (87)       | 214 (92)                      | 188 (81)                          |          |
| Missing                                                                  | 5 (1)          | 3 (1)                         | 2 (1)                             |          |
| **Education**                                                            |                |                               |                                   |          |
| No formal education                                                      | 217 (47)       | 133 (57)                      | 84 (36)                           | <0.001   |
| Less than primary                                                        | 67 (14)        | 30 (13)                       | 37 (16)                           |          |
| Up to secondary                                                         | 149 (32)       | 57 (24)                       | 92 (40)                           |          |
| Higher secondary and above                                              | 30 (7)         | 13 (6)                        | 17 (7)                            |          |
| Missing                                                                  | 2 (<1)         | 1 (<1)                        | 1 (<1)                            |          |
| **Occupation**                                                           |                |                               |                                   |          |
| Unemployed                                                               | 59 (13)        | 31 (13)                       | 28 (12)                           | 0.283    |
| Studying                                                                | 24 (5)         | 8 (3)                         | 16 (7)                            |          |
| Homemaker                                                               | 82 (18)        | 45 (19)                       | 37 (16)                           |          |
| Daily wage labour                                                       | 178 (38)       | 95 (41)                       | 83 (36)                           |          |
| Employed – not daily wage                                               | 113 (24)       | 52 (22)                       | 61 (26)                           |          |
| Missing                                                                  | 9 (2)          | 3 (1)                         | 6 (3)                             |          |
| **Monthly income per capita (US$)**                                     | 15.7 (7.4, 31.4) | 13.1 (6.4, 23.6) | 15.7 (7.9, 31.4) | 0.014 |
| **Clinical characteristics**                                             |                |                               |                                   |          |
| TB in household in the past                                             |                |                               |                                   |          |
| Yes                                                                      | 116 (25)       | 54 (23)                       | 62 (27)                           | 0.321    |
| No                                                                       | 347 (75)       | 180 (77)                      | 167 (72)                          |          |
| Missing                                                                  | 2 (<1)         | 0 (0)                         | 2 (1)                             |          |
| TB death in the household                                               |                |                               |                                   |          |
| Yes                                                                      | 51 (11)        | 27 (11)                       | 24 (10)                           | 0.704    |
| No                                                                       | 413 (89)       | 207 (89)                      | 206 (89)                          |          |
| Missing                                                                  | 1 (<1)         | 0 (0)                         | 1 (<1)                            |          |
| History of fever                                                         |                |                               |                                   |          |
| Yes                                                                      | 350 (75)       | 170 (73)                      | 180 (78)                          | 0.231    |
| No                                                                       | 105 (22)       | 58 (25)                       | 47 (20)                           |          |
| Missing                                                                  | 10 (3)         | 6 (2)                         | 4 (2)                             |          |
| History of weight loss                                                   |                |                               |                                   |          |
| Yes                                                                      | 340 (73)       | 159 (68)                      | 181 (78)                          | 0.032    |
| No                                                                       | 113 (24)       | 66 (28)                       | 47 (20)                           |          |
| Missing                                                                  | 12 (3)         | 9 (4)                         | 3 (2)                             |          |
| History of haemoptysis                                                  |                |                               |                                   |          |
| Yes                                                                      | 119 (26)       | 60 (25)                       | 59 (26)                           | 0.937    |
| No                                                                       | 336 (72)       | 168 (72)                      | 168 (73)                          |          |
| Missing                                                                  | 10 (2)         | 6 (3)                         | 4 (1)                             |          |
| Current smoker                                                          |                |                               |                                   |          |
| Yes                                                                      | 113 (24)       | 65 (28)                       | 48 (21)                           | 0.122    |
| No                                                                       | 343 (74)       | 164 (70)                      | 179 (77)                          |          |
| Missing                                                                  | 9 (2)          | 5 (2)                         | 4 (2)                             |          |
| Current alcohol intake                                                  |                |                               |                                   |          |
| Yes                                                                      | 130 (28)       | 61 (26)                       | 69 (30)                           | 0.419    |
| No                                                                       | 327 (70)       | 168 (72)                      | 159 (69)                          |          |
| Missing                                                                  | 8 (2)          | 5 (2)                         | 3 (1)                             |          |
| Sputum grading                                                          |                |                               |                                   |          |
| 3+                                                                       | 83 (18)        | 34 (15)                       | 49 (21)                           | 0.068    |
| Scanty/1+/2+                                                            | 365 (79)       | 190 (81)                      | 175 (76)                          |          |
| Positive not quantified                                                 | 17 (4)         | 10 (4)                        | 7 (3)                             |          |
| Weight (kg)                                                             |                |                               |                                   |          |
| <30                                                                      | 8 (2)          | 6 (2)                         | 3 (1)                             | 0.540    |
| 30–44.9                                                                 | 200 (43)       | 102 (44)                      | 98 (42)                           |          |
| ≥45                                                                      | 96 (21)        | 44 (19)                       | 52 (23)                           |          |
| Missing                                                                  | 161 (35)       | 83 (35)                       | 78 (34)                           |          |
| Mean (SD)                                                               | 41 (7)         | 41 (6)                        | 41 (7)                            | 0.781    |
| HIV status                                                              |                |                               |                                   |          |
| Positive                                                                 | 1 (<1)         | 0 (0)                         | 1 (<1)                            |          |
| Negative                                                                | 287 (59)       | 143 (61)                      | 144 (62)                          |          |
| Missing                                                                  | 177 (38)       | 91 (39)                       | 86 (37)                           |          |

(Continued)
**Table 2. (Continued).**

| Variable                          | Total [N = 465] | Axshya SAMVAD group [N = 234] | Non-Axshya SAMVAD group [N = 231] | p value* |
|-----------------------------------|-----------------|-------------------------------|-----------------------------------|----------|
| DM status                         |                 |                               |                                   |          |
| DM                               | 9 (2)           | 4 (2)                         | 5 (2)                             | 0.784    |
| Not DM                            | 171 (37)        | 84 (36)                       | 87 (38)                           |          |
| Missing                           | 285 (61)        | 146 (62)                      | 139 (60)                          |          |
| Health-system characteristics     |                 |                               |                                   |          |
| Distance of residence from DMC in kilometre |       |                               |                                   |          |
| ≤ 5                               | 118 (25)        | 50 (21)                       | 68 (29)                           | 0.063    |
| 6–10                              | 144 (31)        | 80 (34)                       | 64 (28)                           |          |
| 11–15                             | 107 (23)        | 49 (21)                       | 58 (25)                           |          |
| > 15                              | 96 (21)         | 55 (24)                       | 41 (18)                           |          |
| Median (IQR)                      | 10 (5,15)       | 10 (6, 15)                    | 10 (5, 14)                        | 0.090    |

Column percentage.

TB: tuberculosis; SAMVAD: sensitisation and advocacy in marginalised and vulnerable areas of the district; SD: standard deviation; HIV: human immunodeficiency virus; DM: diabetes mellitus; DMC: designated microscopy centre; IQR: interquartile range. Axshya SAMVAD: an active case finding strategy under project Axshya implemented by The Union, South East Asia office, New Delhi, India, across 285 districts of India.

*p value calculated after excluding missing values, chi square test/independent t test/Mann–Whitney U test.

Average Indian rupee to USD conversion rate in January 2018 (US$1 = 63.6 Indian rupees), Indian rupee value used for calculating p value.

*History of fever/significant weight loss/haemoptysis between eligibility for sputum examination and diagnosis.

Consumption of alcohol/smoke form of tobacco anytime in the month before date of diagnosis.

*Number with HIV very low (n = 1); hence, p value not calculated.

**Costs due to TB diagnosis**

The median direct medical (US$ 3.3 versus 15.7, p < 0.001), direct non-medical (0.3 versus 1.9, p < 0.001), indirect (US$ 0.1 versus 0.6, p < 0.001) and total costs due to TB diagnosis (US$ 4.6 and 20.4, p < 0.001) were lower in the Axshya SAMVAD group than in the non-Axshya SAMVAD group; however, the difference was not statistically significant for total costs incurred when visiting the private sector (Table 3). The proportion of ‘zero’ total costs (13.4% and 32.5%, p < 0.001) and ‘zero’ costs within each subgroup was also significantly lower in the Axshya SAMVAD group (Table 3).

When we compared each cost component as a proportion of total costs, the Axshya SAMVAD group incurred lower costs for investigations (8.6% versus 13.1%), higher costs for travel (15.7% versus 8.3%), and higher costs for consultations (58.0% versus 44.1%). The proportion of ‘zero’ consultation costs (20.1% and 13.3%) and ‘zero’ costs within each subgroup of consultations was also significantly lower in the Axshya SAMVAD group (Table 3).

**Table 3. Costs and time due to TB diagnosis, stratified by Axshya SAMVAD and non-Axshya SAMVAD groups, among patients with new sputum-smear-positive TB enrolled in Axshya SAMVAD study in India, 2016–2017.**

| Costs (US$)/time due to TB diagnosis | Overall** [N = 465] | Axshya SAMVAD [N = 234] | Non-Axshya SAMVAD [N = 231] | p value* |
|-------------------------------------|----------------------|--------------------------|----------------------------|----------|
| Median (IQR)                        |                      |                          |                            |          |
| Direct medical costs                | 8.3 (0.0, 44.1)      | 3.3 (0.0, 31.5)          | 15.7 (0.8, 58.0)           | <0.001   |
| Consultation fee                    | 0.0 (0.0, 5.2)       | 0.0 (0.0, 3.1)           | 1.5 (0.0, 6.3)             | <0.001   |
| Medicines                           | 2.4 (0.1, 28.3)      | 0.0 (0.1, 18.9)          | 5.9 (0.0, 96)              | 0.005    |
| Investigations                      | 0.0 (0.0, 4.7)       | 0.0 (0.0, 1.3)           | 0.0 (0.0, 7.9)             | <0.001   |
| Direct non-medical costs (travel)   | 1.3 (0.0, 4.7)       | 0.3 (0.0, 3.1)           | 1.9 (0.0, 7.0)             | <0.001   |
| Direct costs (all)                  | 10.9 (0.2, 50.4)     | 4.2 (0.0, 39.5)          | 19.1 (2.1, 67.3)           | <0.001   |
| Indirect costs (wages/income lost)  | 0.3 (0.0, 1.3)       | 0.1 (0.0, 0.8)           | 0.6 (0.2, 1.7)             | <0.001   |
| Total costs                         | 12.5 (0.4, 52.6)     | 4.6 (0.4, 40.1)          | 20.4 (3.6, 66.8)           | <0.001   |
| Total costs – public                | 0.8 (0.0, 2.7)       | 0.4 (0.0, 2.1)           | 1.1 (0.0, 3.1)             | 0.014    |
| Total costs – private               | 20.0 (4.5, 67.6)     | 15.9 (2.1, 58.2)         | 24.2 (6.2, 73.1)           | 0.090    |
| Time spent in hours for consultation| 5.0 (0.0, 16.0)      | 2.0 (0.0, 10.0)          | 8.0 (2.0, 18.0)            | <0.001   |

Column percentage.

IQR: Interquartile range; TB: tuberculosis; SAMVAD: sensitisation and advocacy in marginalised and vulnerable areas of the district. Axshya SAMVAD: an active case finding strategy under project Axshya implemented by The Union, South East Asia office, New Delhi, India, across 285 districts of India. Non-Axshya SAMVAD: patients detected through passive case findings. Total costs information was available from all 465. However, details of time spent in consultation and costs for consultation, medicines, investigations and travel were not available for 11 patients.

*p value calculated after excluding missing values, chi square test/independent t test/Mann–Whitney U test.

Average Indian rupee to USD conversion rate in January 2018 (US$1 = 63.6 Indian rupees), Indian rupee value used for calculating p value.

*History of fever/significant weight loss/haemoptysis between eligibility for sputum examination and diagnosis.

Time spent in hours for consultation.

*p value calculated after excluding missing values, chi square test/independent t test/Mann–Whitney U test.

Median direct medical costs (US$ 3.3 versus 15.7, p < 0.001), direct non-medical costs (0.3 versus 1.9, p < 0.001), indirect costs (US$ 0.1 versus 0.6, p < 0.001) and total costs due to TB diagnosis (US$ 4.6 and 20.4, p < 0.001) were lower in the Axshya SAMVAD group than in the non-Axshya SAMVAD group; however, the difference was not statistically significant for total costs incurred when visiting the private sector (Table 3). The proportion of ‘zero’ total costs (13.4% and 32.5%, p < 0.001) and ‘zero’ costs within each subgroup was also significantly lower in the Axshya SAMVAD group (Table 3).

When we compared each cost component as a proportion of total costs, the Axshya SAMVAD group incurred lower costs for investigations (8.6% versus 13.1%), higher costs for travel (15.7% versus 8.3%), and higher costs for consultations (58.0% versus 44.1%). The proportion of ‘zero’ consultation costs (20.1% and 13.3%) and ‘zero’ costs within each subgroup of consultations was also significantly lower in the Axshya SAMVAD group (Table 3).
Table 4. Contribution of each component of costs due to TB diagnosis as a proportion of total costs, stratified by Axshya SAMVAD and non-Axshya SAMVAD groups, among patients with new sputum-smear-positive TB enrolled in Axshya SAMVAD study in India, 2016–2017 (N = 465).

| Costs due to TB diagnosis as a proportion of total costs | Overall (N = 465) | Axshya SAMVAD (N = 234) | Non-Axshya SAMVAD (N = 231) |
|---------------------------------------------------------|------------------|------------------------|-----------------------------|
| Total costs                                             | 100              | 100                    | 100                         |
| Direct medical costs                                     | 83.3             | 80.8                   | 84.7                        |
| Consultation fee                                        | 12.6             | 13.0                   | 12.3                        |
| Medicines                                               | 59.3             | 59.2                   | 59.3                        |
| Investigations                                          | 11.5             | 8.6                    | 13.1                        |
| Direct non-medical costs (Travel)                       | 11.4             | 15.7                   | 9.1                         |
| Direct costs                                            | 94.7             | 96.5                   | 93.8                        |
| Indirect costs (Wages/income lost)                      | 5.3              | 3.5                    | 6.2                         |

Column percentage.

SAMVAD: sensitisation and advocacy in marginalised and vulnerable areas of the district. Axshya SAMVAD: an active case finding strategy under project Axshya implemented by The Union, South East Asia office, New Delhi, India, across 285 districts of India. Non-Axshya SAMVAD: patients detected through passive case findings.

Total costs information was available from all 465. However, details of time spent in consultation and costs for consultation, medicines, investigations and travel were not available for 11 patients.

9.1%) and lower indirect costs (3.5% versus 6.2%) than the non-Axshya SAMVAD (Table 4).

Prevalence and intensity of catastrophic costs due to TB diagnosis

Due to missing data for either total costs or MIPC in 14 patients, a total 451 patients were included in further analysis. The overall prevalence of catastrophic costs due to TB diagnosis [% (95% CI)] in Axshya SAMVAD and non-Axshya SAMVAD group was 10.3 (6.9, 14.9) and 11.5 (7.9, 16.3) respectively (Table 5), and the difference was not statistically significant (p = 0.064). The median (IQR) intensity of catastrophic costs (expressed as percentage overshoot beyond catastrophic threshold) in Axshya SAMVAD and non-Axshya SAMVAD group was 22 (5, 111) and 37 (9, 87) respectively (p = 0.703).

Effect of Axshya SAMVAD on catastrophic costs

After adjusting for confounders (age, sex, patient education, MIPC, history of weight loss, distance of residence from nearest DMC), patients in the Axshya SAMVAD group had a 32% lower prevalence of catastrophic costs [aPR (95% CI): 0.68 (0.69, 0.97)]. Sputum smear grade, co-morbidities such as HIV and diabetes mellitus did not meet the criteria of potential confounders.

We also did a sensitivity analysis. We repeated the log binomial model, assuming a lower (3.9) and upper range (5.5) of household size in the seven states (to which these 18 districts belonged) [31]. Axshya SAMVAD remained significantly associated with lower catastrophic costs in both these models (Table 5).

Equity assessment

Table 6 summarises the distribution of total costs, total costs as a percentage of pre-TB AHI and catastrophic costs due to TB diagnosis across income quintiles in Axshya SAMVAD and non-Axshya SAMVAD groups. In both the groups, the distribution of total costs did not vary significantly across income quintiles. The distribution of total costs as a percentage of pre-TB AHI and catastrophic costs was significantly higher in the poorest quintiles. This was confirmed by the corresponding concentration curves and indices (Figure 2 and Table 7).

When compared with the non-Axshya SAMVAD group, the concentration index was more negative...
among the Axshya SAMVAD group for all three indicators (Table 7). For the indicator ‘total costs as a proportion of pre-TB AHI’, the Axshya SAMVAD concentration curve dominated over the non-Axshya SAMVAD curve. However, the concentration curves for catastrophic costs were not significantly different (Figure 2 and Table 7).

**Discussion**

ACF among marginalised and vulnerable populations resulted in lower total costs and lower prevalence of catastrophic costs due to TB diagnosis. However, ACF did not address the issue of intensity and inequity in the distribution of catastrophic costs.

**Strengths**

First, in addition to comparing the costs and their catastrophic impact, we also assessed inequity. The comparison group included patients from the same month and from the marginalised/vulnerable populations of the same area as the Axshya SAMVAD patients. Second, similar to Mauch et al. and Morishita et al. [11,23], we included a nationally representative sample, the reference population for

Table 6. Distribution of total costs, total costs as a proportion of pre-TB annual household income and catastrophic costs due to TB diagnosis across income quintiles, stratified by Axshya SAMVAD and non-Axshya SAMVAD groups, among TB (new sputum-smear-positive) affected households in India, 2016–2017 (N = 451).

| Characteristic | Axshya SAMVAD (N = 234) | Non-Axshya SAMVAD (N = 231) |
|---------------|------------------------|-----------------------------|
| Total costs   |                        |                             |
| 1st MIPC quintile | 10.31 (0.13, 57.50)   | 16.89 (2.23, 61.94)        |
| 2nd MIPC quintile | 5.28 (0.37, 81.71)    | 34.13 (7.72, 71.89)        |
| 3rd MIPC quintile | 4.92 (0, 59.20)       | 18.00 (1.89, 69.40)        |
| 4th MIPC quintile | 0.55 (0, 13.32)       | 17.99 (2.22, 59.37)        |
| 5th MIPC quintile | 4.21 (0.27, 39.81)    | 22.17 (7.00, 77.22)        |
| Overall       | 4.64 (0, 40.13)       | 20.36 (3.79, 68.76)        |
| p value       | 0.128                 | 0.528                       |
| Total costs as a percentage of pre-TB annual household income | | |
| 1st MIPC quintile | 6.0 (0.0, 28.0)       | 8.0 (1.0, 36.5)            |
| 2nd MIPC quintile | 1.0 (0.0, 9.0)        | 7.0 (1.0, 14.0)            |
| 3rd MIPC quintile | 1.0 (0.0, 8.0)        | 2.0 (0.0, 6.8)             |
| 4th MIPC quintile | 0.0 (0.0, 1.0)        | 1.0 (0.0, 3.3)             |
| 5th MIPC quintile | 0.0 (0.0, 5.6)        | 1.0 (0.0, 2.0)             |
| Overall       | 0.0 (0.0, 5.6)        | 2.0 (0.0, 8.0)             |
| p value       | <0.001                | <0.001                      |

Catastrophic costs

| Characteristic | Axshya SAMVAD | Non-Axshya SAMVAD |
|---------------|--------------|-------------------|
| 1st MIPC quintile | 31.1         | 31.1              |
| 2nd MIPC quintile | 8.9          | 15.6              |
| 3rd MIPC quintile | 8.3          | 9.1               |
| 4th MIPC quintile | 2.2          | 2.2               |
| 5th MIPC quintile | 0            | 0                 |
| Overall       | 10.3         | 11.5              |
| p value       | <0.001       | <0.001            |

Table 7. Concentration indices for total costs, total costs as a proportion of pre-TB annual household income and catastrophic costs due to TB diagnosis, stratified by Axshya SAMVAD and non-Axshya SAMVAD groups, among TB (new sputum-smear-positive) affected households in India, 2016–2017 (N = 451).

| Characteristics | Axshya SAMVAD | Non-Axshya SAMVAD |
|-----------------|--------------|-------------------|
| Concentration index (95% CI) | p value | Concentration index (95% CI) | p value |
| TOTAL COSTS | -0.15 (-0.32, 0.11) | 0.068 | -0.06 (-0.20, 0.08) | 0.401 |
| CATASTROPHIC COSTS | -0.77 (-1.14, -0.40) | <0.001 | -0.63 (-0.92, -0.34) | <0.001 |

TB: tuberculosis; SAMVAD: sensitisation and advocacy in marginalised and vulnerable areas of the district; Axshya SAMVAD: an active case finding strategy under project Axshya implemented by The Union, South East Asia office, New Delhi, India, across 285 districts of India; non-Axshya SAMVAD: patients detected through passive case findings; MIPC: monthly income per capita.

p value to assess whether the distribution of the indicator was significantly different across the income quintiles (Kruskal–Wallis test for total costs and total costs as a percentage of pre-TB annual household income; chi square test for catastrophic costs).

Total costs due to TB diagnosis more than 20% of pre-TB annual household income.

Non-dominance (both curves not significantly different).

Non-dominance (both curves not significantly different).

Non-dominance test [30].

For details on the dominance test, readers are requested to refer to O’Donnell et al. [30].

Total costs due to TB diagnosis more than 20% of pre-TB annual household income.

Total costs due to TB diagnosis more than 20% of pre-TB annual household income.
which was limited to the Axshya districts (n = 285). The findings are also representative of their respective reference populations with potential contaminated exposures excluded. Third, we ensured quality control through audio recording of all the interviews followed by a random check by supervisors to reduce interviewer bias. We used an innovative resource-efficient model, which helped in near real-time data sharing and monitoring [26].

Finally, double data entry and validation minimised data-entry errors.

**Limitations**

There were several major limitations. First, we did not enrol patients with initial loss to follow-up, and of those enrolled, we could not conduct interviews for 108 (19%). We compared patients and
found that patients residing in rural areas and those with a high sputum grade were more likely to be excluded in our study (Table S2). It is likely that patients in rural areas and those with a high sputum grade may have incurred relatively more costs while undergoing diagnosis, and so our study results may be an underestimate of the key outcomes. Second, patients may have had challenges in recalling information on costs incurred. This recall limitation was non-differential, as it was similar in both the groups (similar delay from enrolment to interview; see Table S3).

Third, we derived the pre-TB AHI from MIPC by assuming an average household size of 4.8. However, while analysing the effect of Axshya SAMVAD on catastrophic costs, we also did a sensitivity analysis for varying household sizes. The findings were consistent and, thus, robust.

Finally, we were expecting most of the consultations for TB diagnosis to be for outpatients, and existing social insurance mechanisms in India do not cover for these. Similarly, food and stay costs are not expected to be significant for outpatient consultations. While we did not assess these parameters, we do not expect these to be differential among both the groups.

**Interpretation of key findings**

Limitations notwithstanding, our study had many key findings. Costs (total and each component) were lower in the ACF group. ACF prevented one-third of the catastrophic costs due to TB diagnosis in all patients detected through ACF. These were possibly mediated through a lower number of visits to HCPs (median one versus two) and a higher proportion with zero visits (22% versus 0%) and first visit to an HCP in a public facility (42% versus 26%) in the Axshya SAMVAD group (data not shown). The costs due to TB diagnosis, total and each component, across ACF and PCF groups, were more or less similar to the findings of Morishita et al. (Table S4). Though the prevalence of catastrophic costs due to TB (diagnosis and treatment) among the ACF group was lower than in the PCF group, Morishita et al. did not find any significant differences (36.1% versus 45.0%, \( p = 0.244 \)). This could be because of the low sample size (around 100 in each arm) and lack of a confounder-adjusted analysis. However, they did not provide catastrophic costs due to the TB diagnosis [23].

Similarly, we identified many studies in the recent period that determined catastrophic costs due to TB care (diagnosis and treatment), but did not provide data specifically for diagnosis [11,33–36]. A systematic review from Africa (studies from 1990 to 2010) revealed that the pre-diagnostic costs for TB varied between 10.4 and 35% of pre-TB AHI [12]. Before TB treatment, indirect costs predominate, and medical costs contribute to most of the direct costs [8]. As we collected information on income loss for the time spent on consultation and not for the work absenteeism due to illness, the contribution of indirect costs to total costs was low (<10%). For this reason, our estimate of catastrophic costs due to TB diagnosis is a conservative one.

The total costs incurred were similar across income quintiles. As a result of this, total costs as a proportion of pre-TB AHI and catastrophic costs were concentrated in the poorest two income quintiles. These findings are consistent with findings globally [8,37].

Although ACF had an effect on both total costs and catastrophic costs, it did not reduce the inequity in their distribution. ACF was associated with more inequity in the distribution of total costs as a proportion of pre-TB AHI (when compared with PCF). This could be explained by the fact that the households of patients detected through ACF had a significantly lower MIPC than through PCF (Table 2).

**Implications for policy and practice**

Project Axshya is planning to continue Axshya SAMVAD in the next phase from 2018 to 2020. India’s national strategic plan to eliminate TB (2017–2025) recommends ACF among clinically, socially and occupationally vulnerable populations over and above the existing PCF strategies under RNTCP [38]. This study provides evidence in support of this.

However, there is a need to address the issue of inequity, irrespective of whether TB patients are identified by ACF or PCF. Globally, it is estimated that even with aggressive expansion of TB services (includes multi-drug resistant TB services and ACF), catastrophic costs would decrease only by 5–20% by 2035 (base year: 2015) [39]. Hence, countries need to move towards universal health coverage and social protection. Universal health coverage is expected to reduce the direct medical costs, and social protection is expected to protect against direct non-medical and indirect costs [3–7].

India has proposed a national health protection scheme that would protect 100 million poor households against catastrophic costs with an annual cover of ≈US$7800. However, this is only for hospitalisations and might have a limited effect on reducing costs due to TB diagnosis [40]. India might take lessons from China where, despite social insurance schemes, the catastrophic costs due to TB have
decreased marginally with no effect on inequity. One of the reasons was limited outpatient costs coverage [35,37,41].

Under social protection, Rudgard et al. [42] suggested that a TB-specific approach (cash transfers for households with a confirmed case of TB) is more effective and affordable than a TB-sensitive (cash transfers for households with a high TB risk to strengthen their economic resilience) approach to reduce TB-specific catastrophic costs. The Government of India has announced the implementation of direct benefit transfer of ≈US$8 per month up to treatment completion for all patients notified with TB (TB-specific approach) [3,38,42,43]. Further research is recommended to assess the benefits of TB-specific cash transfers on catastrophic costs due to TB, including inequity in India.

Conclusion

This study highlights the importance of ACF among the marginalised and vulnerable population in mitigating catastrophic costs due to TB diagnosis. ACF among marginalised and vulnerable populations reduced total costs and prevalence of catastrophic costs. However, ACF did not address intensity and inequity in catastrophic costs. This signals a need for implementation of universal health coverage and social protection, in addition to ACF, which will benefit the poorest of the poor. India has taken steps in the right direction, and this needs to be closely monitored if India has to meet the End TB target of ‘zero’ catastrophic costs due to TB, 10 years before the global target of 2035 [3,38].

Acknowledgements

We thank the following for their support in data collection: Robinson Robert, Madhu Nema, Yashpal Singh Rajput. We would also like to thank other Project Axshya staff: Anand Das, M Ganesh, A. Mary Mamatha, Antony Santhappan, Prabhat Kumar Singh, Deepak Tiggia, Khumanthem Jayanta Kumar Singh, Kamlesh Kumar and Ranjan Singh who participated in the initial training, planning and/or questionnaire development. We would also like to thank the RNTCP staff in the study districts that supported the District Coordinators and Interpersonal Communication Coordinator in study participant enrolment and record review. We thank the Department for International Development (DFID), UK, for funding the Global Operational Research Fellowship Programme at the International Union Against Tuberculosis and Lung Disease (The Union), Paris, France in which HDS and JPT work as a senior operational research fellows.

Author contributions

HDS was the principal investigator involved in all stages of the study; HDS, VG, SS, SSC, AMVK, KDS, KNS, LM, SK, AK, MD, NS and RR were involved in conception and study design; HDS, VG, KDS and SSC were involved in piloting the data-collection tools; PP, UNB, JPT, KDS, PS, KDS, RS, GJ, PR, BKs, MB, GM, OPB, SM, SP, AIJJ, AJN, PV, MSA, PCM, GS, SB, VM, MRSL, GSG, GP, SYB, IK, AKB, GV, KS, JL, AKS, KDS, VHG, BMP and SN were involved in data collection and/or monitoring/supervision of data collection; HDS and JPT were involved in data entry; HDS, VG, SS, SSC, AMVK, KNS, LM, SK, AK, MD, NS, SK and RR were involved in analysis and interpretation of data; HDS, VG, SS, SSC and AMVK were involved in preparing the first draft. All authors read the draft, provided comments and approved the final manuscript; RR, AMVK and SSC were involved in overall supervision and are senior authors.

Disclosure statement

None of the authors have any competing interests. The contents of this paper do not necessarily reflect the views of the Government or Non-Governmental Organizations or The Union.

Ethics and consent

Ethics approval was obtained from the Ethics Advisory Group of The Union, Paris, France (EAG number 15/15, dated 28 September 2015). The study was conducted after receiving approvals from the RNTCP programme in the respective states. Written informed consent was taken from the study participants before the interview (separately for audio recording as well), and the consent process was approved by the ethics committee.

Funding information

The author(s) received no specific funding for this study. We thank The Union South-East Asia Office, New Delhi, India for funding this open-access publication. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors would like to acknowledge funding support for Project Axshya from The Global Fund TB grant to India. The Project has been implemented by the Project Management Unit of The Union South East Asia Office since 2010 to date with the support of the sub-recipient partners (in alphabetical order): The Catholic Bishops’ Conference of India-Coalition for AIDS and Related Diseases (CBCI-CARD); The Catholic Health Association of India (CHAI); Emmanuel Hospital Association (EHA); MAMTA Health Institute for Mother and Child; Population Services International (PSI); Resource Group for Education and Advocacy for Community Health (REACH); and Voluntary Health Association of India (VHAI).

Paper context

Patients incur significant direct medical, direct non-medical and indirect costs due to TB care. Community-based active case finding for Tuberculosis in marginalised populations reduced total costs and catastrophic costs (more than 20% of AHI) due to TB diagnosis. It did not address the intensity of catastrophic costs and inequity. This calls for
implementation of universal health coverage and social protection, in addition to active case finding, which will benefit the poorest of the poor.

**ORCID**

Hemant Deepak Shewade [http://orcid.org/0000-0002-8242-1911](http://orcid.org/0000-0002-8242-1911)

**References**

[1] World Health Organization (WHO). Global tuberculosis report 2017. WHO/HTM/TB/2017.23. Geneva (Switzerland). 2017.

[2] World Health Organization (WHO). Tuberculosis patient cost survey: a handbook. Geneva (Switzerland): World Health Organization; 2017.

[3] World Health Organization (WHO). End TB Strategy. WHO/HTM/TB/2015.19. Geneva (Switzerland). 2015.

[4] World Health Organization (WHO). Contributing to health system strengthening - Guiding principles for national tuberculosis programmes. WHO/HTM/TB/2008.400. Geneva (Switzerland); 2008.

[5] World Health Organization (WHO). World Health Report 2010: health systems financing - the path to universal coverage. Geneva (Switzerland): World Health Organization; 2010.

[6] International Labour Organization. A joint crisis initiative of the UN Chief Executives Board for co-ordination on the social protection floor. Geneva (Switzerland): International Labour Organization; 2009.

[7] International Labour Organization. World social security report 2010/11: providing coverage in times of crisis and beyond. Geneva (Switzerland): International Labour Organization; 2010.

[8] Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: A systematic review. Eur Respir J. 2014;43:1763–1775.

[9] World Health Organization (WHO). Systematic screening for active tuberculosis: an operational guide. Geneva (Switzerland): World Health Organization; 2015.

[10] Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8:15.

[11] Mauch V, Bonsu F, Gyapong M, et al. Free tuberculosis diagnosis and treatment are not enough: patient cost evidence from three continents. Int J Tuberc Lung Dis. 2013;17:381–387.

[12] Ukwaja KN, Modebe O, Igwenyi C, et al. The economic burden of tuberculosis care for patients and households in Africa: a systematic review. Int J Tuberc Lung Dis. 2012;16:733–739.

[13] Atun R, Weil DEC, Eang MT, et al. Health-system strengthening and tuberculosis control. Lancet. 2010;375:2169–2178.

[14] Lönnroth K, Glaziou P, Weil D, et al. Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention. PLoS Med. 2014;11:e1001693.

[15] Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010;375:1814–1829.

[16] Revised National Tuberculosis Control Programme (RNTCP). TB India 2018. Annual status report. New Delhi (India): Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; 2018.

[17] Sachdeva KS, Kumar A, Dewan P, et al. New vision for Revised National Tuberculosis Control Programme (RNTCP): universal access - "reaching the un-reached". Indian J Med Res. 2012;135:690–694.

[18] International Union Against Tuberculosis and Lung Disease (The Union). Project Axshya [Internet]. 2016 [cited 2016 Nov 15]. Available from: [http://axshyatheunion.org/](http://axshyatheunion.org/)

[19] International Union Against Tuberculosis and Lung Disease (The Union). Project Axshya, Annual Report [Internet]. 2016 [cited 2017 Apr 9]. Available from: [http://axshyatheunion.org/annual-report-2/](http://axshyatheunion.org/annual-report-2/)

[20] Stop TB Partnership. Axshya SAMVAD goes door-to-door to fight TB [Internet]. 2014 [cited 2016 Jun 8]. Available from: [http://www.stopthb.org/news/frompartners/2014/fp14_085.asp](http://www.stopthb.org/news/frompartners/2014/fp14_085.asp)

[21] Prasad BM, Satyanarayana S, Chadha SS, et al. Experience of active tuberculosis case finding in nearly 5 million households in India. Public Health Action. 2016;6:15–18.

[22] World Health Organization (WHO). Scoping meeting for the development of guidelines on screening for active TB. Geneva (Switzerland): World Health Organization; 2011.

[23] Morishita F, Yadav R-P, Eang MT, et al. Mitigating financial burden of tuberculosis through active case finding targeting household and neighbourhood contacts in Cambodia. PLoS One. 2016;11:e0162796.

[24] Veesa KS, John KR, Moonan PK, et al. Diagnostic pathways and direct medical costs incurred by new adult pulmonary tuberculosis patients prior to anti-tuberculosis treatment - Tamil Nadu, India. PLoS One. 2018;13:e0191591.

[25] Revised National Tuberculosis Control Programme (RNTCP). Central TB Division. Ministry of Health and Family Welfare. Government of India. Technical and operational guidelines for tuberculosis control in India. New Delhi (India): Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; 2016.

[26] Shewade HD, Chadha SS, Gupta V, et al. Data collection using open access technology in multicentre operational research involving patient interviews. Public Health Action. 2017;7:74–77.

[27] Planning Commission, Government of India. Report of the expert group to review the methodology for measurement of poverty. New Delhi (India): Planning Commission, Government of India; 2014.

[28] Lionel Demery. Benefit incidence analysis [Internet]. 1999 [cited 2018 Feb 8]. Available from: [http://sitereources.worldbank.org/EXTEDSTATS/Resources/3232763-1171296308277/3445908-1171296572010/Analysis.html](http://sitereources.worldbank.org/EXTEDSTATS/Resources/3232763-1171296308277/3445908-1171296572010/Analysis.html)

[29] McIntyre D, Ataguba JE. How to do (or not to do) ... a benefit incidence analysis. Health Policy Plan. 2011;26:174–182.

[30] O’Donnell O, van Doorslaer E, Wagstaff A, et al. Analyzing health equity using household survey data. Washington (DC): The World Bank; 2007.
[31] Government of India. Ministry of Home Affairs. Office of Registrar General and Census Commissioner. Census of India [Internet]. 2011 [cited 2016 May 27]. Available from: http://www.censusindia.gov.in/2011-common/census_2011.html

[32] Bursac Z, Gauss CH, Williams DK, et al. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.

[33] Laokri S, Dramaix-Wilmet M, Kassa F, et al. Assessing the economic burden of illness for tuberculosis patients in Benin: determinants and consequences of catastrophic health expenditures and inequities. Trop Med Int Health. 2014;19:1249–1258.

[34] Wingfield T, Boccia D, Tovar M, et al. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. PLoS Med. 2014;11:e1001675.

[35] Zhou C, Long Q, Chen J, et al. The effect of NCMS on catastrophic health expenditure and impoverishment from tuberculosis care in China. Int J Equity Health. 2016;15:172.

[36] Zhou C, Long Q, Chen J, et al. Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China. Infect Dis Poverty. 2016;5:6.

[37] Xiang L, Pan Y, Hou S, et al. The impact of the new cooperative medical scheme on financial burden of tuberculosis patients: evidence from six counties in China. Infect Dis Poverty. 2016;5:8.

[38] Revised National Tuberculosis Control Programme (RNTCP). Central TB Division. National strategic plan for TB elimination 2017-25. New Delhi (India): Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; 2017.

[39] Verguet S, Riumallo-Herl C, Gomez GB, et al. Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. Lancet Glob Heal. 2017;5:e1123–e1132.

[40] Press Information Bureau; Government of India. Cabinet approves Ayushman Bharat – National Health Protection Mission [Internet]. 2018 [cited 2018 Mar 31]. Available from: http://pib.nic.in/newsite/PrintRelease.aspx?relid=177816

[41] Meng Q, Fang H, Liu X, et al. Consolidating the social health insurance schemes in China: towards an equitable and efficient health system. Lancet. 2015;386:1484–1492.

[42] Rudgard WE, Evans CA, Sweeney S, et al. Comparison of two cash transfer strategies to prevent catastrophic costs for poor tuberculosis-affected households in low- and middle-income countries: an economic modelling study. PLoS Med. 2017;14:e1002418.

[43] Ministry of Health and Family Welfare Government of India. Gazette Notification For DBT with NIKSHAY. D.O. No. Z-28015/24/2017-TB [Internet]. 2017 [cited 2018 Mar 29]; [p. 1–17]. Available from: https://tbcindia.gov.in/showfile.php?lid=3304